Current treatment guidelines advocate the use of triple combination antiretroviral therapy for the management of human immunodeficiency virus (HIV) infection with one protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) plus two nucleoside reverse transcriptase inhibitors (NRTIs). Additionally, patients often receive medications for prophylaxis and treatment of opportunistic infections and comorbid illnesses. Polypharmacy with potent medications places the patient with HIV at significant risk of drug interactions. The purpose of this review is to assist clinicians regarding awareness and management of clinically significant drug interactions frequently encountered in the HIV population.
Pharmacodynamic and pharmacokinetic interactions are discussed in depth with several tables of significant interactions encountered in the patient with HIV. Certain combinations of NRTIs have antagonistic antiretroviral action (e.g., zidovudine plus stavudine), and thus should be avoided. All of the currently available PIs and delavirdine are cytochrome (CYP) 450 inhibitors and can cause significant inhibition of concomitant drug metabolism. Nevirapine is a CYP 450 inducer and can cause induction of drug metabolism, whereas efavirenz may cause inhibition or induction. Drug-herbal interactions are reviewed, including the decreased concentrations of indinavir following the administration of St. John’s wort. Additionally, the pharmacist’s role as an integral member of the HIV patient care team is discussed.
Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society—USA Panel. JAMA. 2000; 283:381-390.
2.
Hammer S, Squires K, Hughes M, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997; 337:725-733.
3.
Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998; 351:543-549.
4.
Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998; 338:853-860.
5.
Fogelman I, Lim L, Bassett R, et al. Prevalence and patterns of use of concomitant medications among participants in three multicentre human immunodeficiency virus type 1 clinical trials. J Acq Immune Def Syndromes. 1994; 7:1057-1063.
6.
Steel K, Gertman PM, Cresienze G, et al. Iatrogenic illness on a general medical service at a university hospital. N Engl J Med. 1981; 304:638-642.
7.
Piscitelli SC, Flexner C, Minor JR, et al. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996; 23:685-693.
8.
Tseng AL, Foisy MM. Management of drug interactions in patients with HIV. Ann Pharmacother. 1997; 31:1040-1058.
9.
Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet. 1999; 36(4):289-304.
10.
Tseng AL, Foisy MM. Significant interactions with new antiretrovirals and psychotic drugs. Ann Pharmacother. 1999; 33:461-473.
11.
Hansten PD, Horn JR. Drug Interactions Analysis and Management. Missouri: Facts and Comparisons; 1999.
12.
Erron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med. 1995; 333:1662-1669.
13.
Hoggard PG, Kewn S, Barry MG, et al. Drug interactions with d4T phosphorylation in vitro. Antimicrob Agents Chemother. 1997; 41:1231-1236.
14.
Havlir DV, Freidland G, Pollard R, et al. Combination zidovudine (ZDV) and stavudine (d4T) therapy versus other nucleosides: report of two randomised trials ACTG 290 and 298 (abstract). 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago.
15.
Veal GJ, Hoggard PG, Barry MG, et al. Interaction between 3TC (lamivudine) and other nucleoside analogues for intracellular phosphorylation. AIDS. 1996; 10:546-548.
16.
Kewn S, Veal GJ, Hoggard PG, et al. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem Pharmacol. 1997; 54:589-595.
17.
Ruiz L, Romeu J, Martinez-Picado J, et al. Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitibine (ddC) plus lamivudine (3TC) versus double (ZDV + 3TC) combination therapy in patients previously treated with ZDV + ddC. AIDS. 1996; 10: F61-F66.
18.
Lee BL, Safrin S.Interactions and toxicities of drugs used in patients with AIDS. Clin Infect Dis. 1992; 14:773-779.
19.
Burger DM, Meenhorst PL, Koks CHW, et al. Drug interactions with zidovudine. AIDS. 1993; 7:445-460.
20.
Hochster H, Dieterich D, Bozzette S, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS: an AIDS clinical trials group study. Ann Intern Med. 1990; 113:111-117.
Crixivan package insert. West Point, PA: Merck & Co; 1999 Sept.
26.
Shelton J, Morse GD, Hewitt RG. Gastric hypoacidity among HIV-infected outpatients (abstract). Presented at the 2nd National Conference on Human Retroviruses, Washington, DC, January 29-February 2, 1995.
27.
Chin T.Effects of an acidic beverage (Coca Cola) on the absorption of ketoconazole (abstract). Presented at the 26th Annual Professional Practice Conference, Toronto, Canada, February 5-9, 1995.
28.
Peloquin Ca, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother. 1996; 30: 919-925.
29.
Polk RE. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med. 1989; 87(suppl 5A):76S-81S.
30.
Sahai J, Gallicano K, Oliveras L, et al. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther. 1993; 53:292-297.
31.
Nix DEet al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther. 1989; 46:700.
32.
Hurwitz A, Scholzman DI. Effects of antacids on gastric absorption of isoniazid in rat and man. Am Rev Respir Dis. 1974; 109:41-47.
33.
Piscitelli SC, Goss R, Wilton JH, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991; 35:1765-1771.
34.
Blum RA, D’Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991; 114: 755-757.
Frascino RJ, Gaines Griffey K, Jung D, et al. Multiple dose crossover study of iv ganciclovir induction dose (5 mg/kg iv q 12h) and didanosine (200 mg po q12h) in HIV-infected persons (abstract). Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995.
37.
Agenerase package insert. Research Triangle Park, NC: Glaxo Wellcome; 1999 Oct.
38.
Norvir package insert. North Chicago, IL: Abbott Laboratories; 2000 March
Sustiva package insert. Wilmington, DE: Du Pont Pharma; 2000 Feb.
41.
Mepron package insert. Research Triangle Park, NC: Glaxo Wellcome; 1999 Jan.
42.
Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998; 19(1):84-112.
43.
Sporanox package insert. Titusville, NJ: Janssen Pharmaceutica; 1997 Aug.
44.
Workman C, Mussen R, Sullivan J.Salvage therapy using six drugs in heavily pretreated patients (abstract). 5th Conference on Retro-viruses and Opportunistic Infections, Chicago, February 1-5, 1998.
45.
Viramune package insert. Columbus, OH: Roxane Laboratories; 1999 July 8.
46.
Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med. 1998; 158:2200-2211.
47.
Fairfield KM, Eisenberg DM, Davis RB, et al. Patterns of use, expenditures and perceived efficacy of complementary and alternative therapies in HIV infected patients. Arch Intern Med. 1998; 158:2257-2264.
48.
Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St. John’s Wort. Lancet. 2000; 355:547-548.
49.
Kaletra. December 7, 2000. Center for Drug Evaluation and Research [cited 2000, Sept 15]. Available from: URL: http://www.fda.gov/cder/drug/infopage/kaletra/default.htm
